> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Regulatory Review Period Determined for Lenvima
- URL: https://www.fdaweb.com/regulatory-review-period-determined-for-lenvima/
- Published: 2018-02-02T12:00:00.000Z
- Updated: 2026-09-14T23:19:19.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5140671

*Federal Register* notice: FDA has determined for patent extension purposes that the regulatory review period for Lenvima (lenvatinib mesylate) is 3,580 days. Of this time, 3,396 days occurred during the testing phase and 184 days during the approval phase. Lenvima is indicated for treating patients with locally recurrent or metastatic, progressive, radioactive iodine- refractory differentiated thyroid cancer. To view the notice, click [here](https://www.gpo.gov/fdsys/pkg/FR-2018-01-31/pdf/2018-01920.pdf?ref=fdaweb.com).